GNRH1 and ovarian hyperstimulation syndrome: Recent findings have demonstrated how in PCOS patients with high anti-Müllerian hormone (AMH) levels, the letrozole co-administration to GnRH-ant protocols results in a lower OHSS incidence than conventional GnRH-ant protocols.